Multi-joint-detection detection card for detecting diabetes mellitus typing, preparation method, kit and determination method

Through multi-joint detection card and fluorescent microsphere labeling technology, the problem of the inability of the existing technology to detect diabetes typing simultaneously is solved, and the rapid accuracy and low-cost detection of early diagnosis of diabetes is achieved, and the operation process is simplified.

CN118937663APending Publication Date: 2024-11-12DAAN GENE CO LTD

Patent Information

Application Number
CN202310528279.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art cannot simultaneously detect glutamate decarboxylase antibodies, insulin autoantibodies and islet cell antibodies, resulting in the inability to diagnose diabetes early, and the existing detection methods are complex in operation, high cost and low sensitivity.

Method used

Using a multi-coupled detection card, including test strips and kits, through fluorescent microsphere labeling technology and immunofluorescence analyzer, three antibodies can be detected simultaneously, simplifying the operation process, reducing costs, and improving detection sensitivity.

Benefits of technology

It achieves rapid and accurate early detection of diabetes, simple operation, short detection time and low cost, and can detect three biomarkers at the same time to meet the needs of clinical application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937663A_ABST
    Figure CN118937663A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biomedical detection, and relates to a multi-joint detection card for detecting diabetes mellitus typing, the detection card comprises a test strip, the test strip comprises a sample pad, a combination pad, a reaction film, an absorption pad and a bottom plate; a first detection line, a second detection line, a third detection line and a quality control line which are parallel to one another are arranged on the reaction film; the conjugate pad is coated with a glutamic acid decarboxylase antigen, an insulin antigen and an islet cell autoantigen which are respectively marked by fluorescent microspheres; the first detection line is coated with a glutamate decarboxylase antigen; the second detection line is coated with an insulin antigen; the third detection line is coated with islet cell autoantigen; and the quality control line is coated with a goat anti-mouse IgG monoclonal antibody. The invention also provides a preparation method of the multi-joint detection card for detecting diabetes mellitus typing, a kit and a determination method. The method is simple to operate, short in detection time, high in sensitivity, wide in linear range and accurate in result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biomedical testing technology, and in particular to a multiple-test card for detecting diabetes typing, a preparation method, a kit and a determination method. Background Art

[0002] Data from the World Health Organization show that the number of people with diabetes has almost quadrupled from 108 million to 463 million between 1980 and 2019, and the prevalence of obesity has been steadily increasing along with this increase in the number of people with diabetes. The prevalence of diabetes in the general population in most countries is between 7% and 14%, and premature mortality attributable to diabetes has also increased by 5% between 2000 and 2016. Moreover, it is predicted that the number of people with diabetes worldwide will increase to 700 million by 2045, and the rapid increase in the prevalence of metabolic diseases is now being recognized as a global health emergency.

[0003] Related studies have shown that autoimmune-mediated destruction of insulin B cells plays a key role in the development of diabetes. Clarifying the expression of pancreatic autoantibodies is conducive to the early diagnosis and classification of diabetes. According to the different pathogenesis of diabetes, it is clinically divided into type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Although the number of T1DM cases is far lower than that of T2DM, it is more common in children and adolescents and can easily cause ketoacidosis, renal failure, and even death. Therefore, early diagnosis and classification are particularly important for the subsequent treatment and prognosis of diabetic patients.

[0004] Glutamic acid decarboxylase antibody (GAD-Ab) is a hallmark antibody of T1DM. It is a non-neural tissue synthetic enzyme. Existing data confirm that its level can increase several years or even more than 10 years before the onset of T1DM. It has the characteristics of high sensitivity and strong specificity. It is considered to be a specific marker of pancreatic islet B cell immune destruction in patients with T1DM. T1DM is an autoimmune disease caused by the destruction of insulin B cells by autoantigen-mediated immune response in genetically susceptible individuals. GAD is the key initiating target antigen of this immune response, which can inhibit the specific autoimmune response caused by it and induce immune tolerance, providing a basis for clinical accurate differentiation of T1DM and T2DM. Insulin autoantibodies (IAA) and islet cell antibodies (ICA) are both insulin B cell autoantibodies and are markers of insulin autoimmune damage. IAA is a marker of insulin autoimmune damage. The changes in the serum of diabetic patients and healthy subjects were measured and it was found that the expression level of IAA was compared in the T1DM group>T2DM group>control group. ICA is a pancreatic B cell cytoplasmic antibody. When the pancreatic cell antibody binds to the pancreatic cell surface antigen, it can cause an immune response, resulting in a cytotoxic effect on the pancreatic cell cytoplasm components, leading to cell lysis and death, and ultimately inducing diabetes. A large number of studies have shown that about 70% of T1DM patients have ICA. It is currently believed that a positive ICA indicates autoimmune damage to pancreatic B cells. When it is persistently positive or at a high level, it has a high predictive value for T1DM.

[0005] Diabetes is a metabolic disease, which is manifested by elevated blood sugar and disordered glucose metabolism. If not treated actively, the biggest threat to patients is that if blood sugar is not effectively controlled for a long time, the invasion range can extend to other organs, inducing various complications, such as heart, kidney, and brain, leading to body function failure and even life-threatening. Intervention for diabetic patients requires the application of relevant drugs and adjustment of lifestyle in combination with changes in blood sugar indicators, so the effectiveness and accuracy of the test methods are extremely important. The determination of glutamic acid decarboxylase antibodies (GAD-Ab), insulin autoantibodies (IAA), and islet cell antibodies (ICA) can evaluate the early stage of diabetes, judge the dynamic development of the disease, and guide clinical medication, which has high clinical value and important significance.

[0006] At present, the commonly used detection methods for glutamic acid decarboxylase antibody (GAD-Ab), insulin autoantibody (IAA), and islet cell antibody (ICA) are chemiluminescence, enzyme-linked immunosorbent assay, dry immunofluorescence, electrochemiluminescence, and colloidal gold colorimetry. Chemiluminescence immunoassay requires a professional chemiluminescence instrument, and most of them are closed systems. Reagents and instruments from different manufacturers are not universal, the cost is high, the operation is time-consuming, and the operator must have special operating skills; enzyme-linked immunosorbent assay uses horseradish peroxidase or alkaline phosphatase to label antibodies, which are used to catalyze the color change of luminescent substrates. The operation is simple, but the marker is easy to inactivate, the luminescent substrate needs to be protected from light, and the detection sensitivity of the reagent is low, resulting in inaccurate test results; dry immunofluorescence is a dry chemical chromatography based on immunofluorescence quantitative detection technology, which has poor activity and will affect the test results; electrochemiluminescence instrument requirements are high, and reagents and instruments are relatively expensive; colloidal gold colorimetry is fast and simple, easy to operate, but it cannot accurately judge the content.

[0007] In view of the problems existing in the current detection methods, it is urgent to invent a diabetes typing detection method with short detection time, high sensitivity, simple operation and low detection cost. In addition, there is currently no multi-detection reagent on the market that can simultaneously and quantitatively detect the three biomarkers of diabetes typing, namely, glutamic acid decarboxylase antibodies, insulin autoantibodies, and islet cell antibodies. Therefore, it is impossible to simultaneously and quantitatively detect multiple biomarkers of diabetes typing, and thus it is impossible to provide a basis for the clinical diagnosis of early diabetes. Summary of the invention

[0008] The purpose of the embodiments of the present application is to propose a multi-test card and preparation method, a kit and a determination method for detecting diabetes typing, so as to solve the technical problem that the prior art cannot simultaneously and quantitatively detect three biomarkers of glutamic acid decarboxylase antibodies, insulin autoantibodies, and islet cell antibodies for detecting diabetes typing.

[0009] In order to solve the above technical problems, the present application embodiment provides a multi-test card for detecting diabetes typing, which adopts the following technical solution:

[0010] The test card comprises a test strip, and the test strip comprises a sample pad, a conjugate pad, a reaction membrane, an absorption pad and a bottom plate;

[0011] The bottom plate is a long strip structure, the reaction membrane is arranged on the surface of the bottom plate, one end of the binding pad is overlapped on one end of the reaction membrane, one end of the absorption pad is overlapped on the other end of the reaction membrane, one end of the sample pad is overlapped on the other end of the binding pad, and the sample pad and the absorption pad are respectively arranged at two ends of the bottom plate; a first detection line, a second detection line, a third detection line and a quality control line are arranged on the reaction membrane in parallel with each other;

[0012] Among them, the binding pad is coated with glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen respectively labeled with fluorescent microspheres; the first detection line is coated with glutamic acid decarboxylase antigen; the second detection line is coated with insulin antigen; the third detection line is coated with pancreatic islet cell autoantigen; the quality control line is coated with sheep anti-mouse IgG monoclonal antibody.

[0013] Furthermore, the sample pad is made of a glass cellulose membrane soaked in a surfactant buffer.

[0014] Furthermore, the surfactant buffer is selected from a boric acid-borax buffer containing bovine serum albumin and Tween 20.

[0015] Furthermore, the binding pad is made of glass cellulose membrane; the reaction membrane is made of nitrocellulose membrane; and the absorption pad is made of H-1 absorbent paper.

[0016] Furthermore, the detection card further comprises a card shell, the card shell comprises a receiving cavity, a sample adding hole and an observation window; the sample adding hole and the observation window are respectively connected with the receiving cavity;

[0017] The test strip is placed in the receiving cavity, the sample adding hole corresponds to the sample pad area, and the observation window corresponds to the reaction membrane area.

[0018] In order to solve the above technical problems, the present application also provides a method for preparing a multi-test card for detecting diabetes typing, which adopts the following technical solution:

[0019] A sample pad, a conjugation pad, a reaction membrane and an absorption pad are prepared, wherein a first detection line, a second detection line, a third detection line and a quality control line are arranged on the reaction membrane in parallel, wherein the conjugation pad is coated with glutamic acid decarboxylase antigen, insulin antigen and islet cell autoantigen respectively labeled with fluorescent microspheres, the first detection line is coated with glutamic acid decarboxylase antigen, the second detection line is coated with insulin antigen, the third detection line is coated with islet cell autoantigen, and the quality control line is coated with goat anti-mouse IgG monoclonal antibody;

[0020] The reaction membrane is arranged on the bottom plate, one end of the conjugate pad is overlapped on one end of the reaction membrane close to the detection line, one end of the absorption pad is overlapped on the other end of the reaction membrane close to the quality control line, and one end of the sample pad is overlapped on the other end of the conjugate pad to form a test strip;

[0021] Use the test strips to assemble and get the test card.

[0022] Further, the sample pad is prepared by the following steps:

[0023] The glass cellulose membrane is soaked in a surfactant buffer and dried at a temperature of 18 to 26° C. and a relative humidity of ≤30% to prepare a sample pad;

[0024] The conjugate pad is prepared by the following steps:

[0025] Mixing glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen respectively labeled with fluorescent microspheres to obtain labeled antigens;

[0026] Using a quantitative film sprayer, the labeled antigen is uniformly sprayed onto the pretreated glass cellulose membrane, and after drying, a conjugate pad is prepared;

[0027] The reaction film is prepared by the following steps:

[0028] Using coating solution, the goat anti-mouse IgG monoclonal antibody and glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen are diluted to preset concentrations to obtain antibody dilution solution, glutamic acid decarboxylase antigen dilution solution, insulin antigen dilution solution and pancreatic islet cell autoantigen dilution solution;

[0029] The antibody dilution, the glutamic acid decarboxylase antigen dilution, the insulin antigen dilution and the pancreatic islet cell autoantigen dilution are uniformly sprayed on the nitrocellulose membrane using a quantitative film sprayer to form a quality control line, a first detection line, a second detection line and a third detection line which are parallel to each other, and a reaction membrane is obtained after drying.

[0030] Furthermore, the coating solution is a PBS buffer containing sucrose.

[0031] In order to solve the above technical problems, the present application also provides a multiplex test kit for detecting diabetes typing, which adopts the following technical solution:

[0032] The kit comprises the above-mentioned multiple-test card for detecting diabetes typing, a diluent and a chip;

[0033] The diluent is a phosphate buffer; the chip contains standard curve information corresponding to the test glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen.

[0034] In order to solve the above technical problems, the present application also provides a method for detecting diabetes typing using a multiplex test kit, which adopts the following technical solution:

[0035] Add the collected sample into the diluent and mix evenly to obtain a mixed sample;

[0036] Add the mixed sample to the test card, let it stand for a preset time, and then insert the test card into an immunofluorescence analyzer to obtain the test result;

[0037] The test results are calculated according to the standard curve information in the chip to obtain the contents of glutamic acid decarboxylase antibodies, insulin antibodies and islet cell autoantibodies in the sample respectively.

[0038] Compared with the prior art, this application has the following beneficial effects:

[0039] The multi-test card for detecting diabetes typing provided in the present application can simultaneously detect three different markers for diabetes typing, making early detection of diabetes faster and more accurate; the operation is simple and the detection time is short, and only one sample addition is required to obtain three test results. After the sample addition is completed, the result can be obtained within 10min-15min, and the detection time is short and the detection cost is low; the detection card of the present application adopts time-resolved fluorescent microsphere labeling technology, which has high sensitivity, wide linear range, and accurate results, and can better meet clinical applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] In order to more clearly illustrate the scheme in the present application, a brief introduction is given below to the drawings required for use in the description of the embodiments of the present application. Obviously, the drawings described below are some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying any creative work.

[0041] Figure 1 It is a schematic diagram of the structure of the test strip of the multi-test card for detecting diabetes typing of the present application;

[0042] Figure 2 It is a schematic diagram of the structure of an embodiment of the multi-test card for detecting diabetes typing of the present application. DETAILED DESCRIPTION

[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by technicians in the technical field of the present application; the terms used in the specification of the application herein are only for the purpose of describing specific embodiments and are not intended to limit the present application; the terms "including" and "having" and any variations thereof in the specification and claims of the present application and the above-mentioned drawings are intended to cover non-exclusive inclusions. The terms "first", "second", etc. in the specification and claims of the present application or the above-mentioned drawings are used to distinguish different objects, not to describe a specific order.

[0044] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0045] In order to enable those skilled in the art to better understand the solution of the present application, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the accompanying drawings.

[0046] The present application provides a multiple-test card for detecting diabetes typing, which includes a test strip, see Figure 1 As shown, the test strip includes a sample pad 2 , a conjugate pad 3 , a reaction membrane 4 , an absorption pad 9 and a bottom plate 1 .

[0047] The base plate 1 is a long strip structure, the reaction membrane 4 is arranged on the surface of the base plate 1, one end of the binding pad 3 is overlapped on one end of the reaction membrane 4, one end of the absorption pad 9 is overlapped on the other end of the reaction membrane 4, one end of the sample pad 2 is overlapped on the other end of the binding pad 3, and the sample pad 2 and the absorption pad 9 are respectively arranged at two ends of the base plate 1; the reaction membrane 4 is provided with a first detection line (T1 line) 5, a second detection line (T2 line) 6, a third detection line (T3 line) 7 and a quality control line (C line) 8 which are parallel to each other.

[0048] Among them, the conjugate pad 3 is coated with glutamic acid decarboxylase antigen (GAD-Ag), insulin antigen (IAA) and islet cell autoantigen (ICA1) respectively labeled with fluorescent microspheres; the first detection line 5 is coated with glutamic acid decarboxylase antigen; the second detection line 6 is coated with insulin antigen; the third detection line 7 is coated with islet cell autoantigen; and the quality control line 8 is coated with sheep anti-mouse IgG monoclonal antibody.

[0049] The quality control line 8 may also be coated with goat anti-chicken IgG monoclonal antibody or DNP antibody (deoxyribo-nucleoprotein antibody).

[0050] In this embodiment, one side of the absorption pad 9 and one side of the binding pad 3 are respectively overlapped on two opposite sides of the reaction membrane 4, and the surface of the reaction membrane 4 forms a detection area, in which the first detection line 5, the second detection line 6, the third detection line 7 and the quality control line 8 are fixed. The glutamic acid decarboxylase antigen labeled with fluorescent microspheres, the insulin antigen labeled with fluorescent microspheres and the islet cell autoantigen labeled with fluorescent microspheres coated on the binding pad 3 can be used to identify glutamic acid decarboxylase antibodies (GAD-Ab), insulin autoantibodies (IAA) and islet cell antibodies (ICA) of different epitopes.

[0051] It should be noted that the first detection line 5, the second detection line 6 and the third detection line 7 are adjacent to each other, and the first detection line 5, the second detection line 6, the third detection line 7 and the quality control line 8 are respectively flush with the short sides of the base plate 1, the first detection line 5 is close to the binding pad 3, and the quality control line is close to the absorption pad 9.

[0052] In some embodiments, the sample pad 2 is made of a glass cellulose membrane soaked in a surfactant buffer.

[0053] In some embodiments, the surfactant buffer is selected from a boric acid-borax buffer containing bovine serum albumin (BSA) and Tween 20.

[0054] The pH value of Tween 20 is 8.0±0.05; the concentration of boric acid-borax buffer is 0.2M.

[0055] In some embodiments, the conjugate pad 3 is made of glass cellulose membrane; the reaction membrane 4 is made of nitrocellulose membrane; and the absorption pad 9 is made of H-1 absorbent paper.

[0056] In some embodiments, the test card further comprises a card housing 10, see Figure 2 As shown, the cartridge 10 comprises a receiving cavity 11 , a sample adding hole 13 and an observation window 12 ; the sample adding hole 13 and the observation window 12 are respectively connected to the receiving cavity 11 .

[0057] The test strip is placed in the receiving cavity 11 , the sample adding hole 13 corresponds to the sample pad 2 area, and the observation window 12 corresponds to the reaction membrane 4 area.

[0058] Specifically, when the test strip is placed in the receiving cavity 11 of the cartridge 10, the sample pad 2 is exposed through the sample addition hole 13, and the reaction membrane 4 is exposed through the observation window 12. That is, the bottom plate 1, sample pad 2, binding pad 3, reaction membrane 4 and absorption pad 9 of the test strip are all placed in the cartridge 10, and the observation window 12 is provided at a position corresponding to the reaction membrane 4 on the shell surface of the cartridge 10, and the sample addition hole 13 is provided at a position corresponding to the sample pad 2 on the shell surface of the cartridge 10.

[0059] The detection card of the present application adopts a double antigen sandwich method and utilizes the technical principle of fluorescent immunochromatography. During the test, the sample is mixed with the diluent and dripped into the sample addition hole 13 of the detection card. Chromatography is performed under the capillary effect. The GAD antibody, IAA antibody, and ICA antibody in the sample are combined with the glutamic acid decarboxylase antigen labeled with fluorescent microspheres, the insulin antigen labeled with fluorescent microspheres, and the pancreatic islet cell autoantigen labeled with fluorescent microspheres, and diffuse to the reaction membrane 4 of the test area. They are captured by the GAD antigen, IAA antigen, and ICA antigen coated on the first detection line 5, the second detection line 6, and the third detection line 7, and form an "antigen-antibody-fluorescent antigen" complex. The concentration of the GAD antibody, IAA antibody, and ICA antibody in the sample is proportional to the fluorescence intensity of the complex. The content of the corresponding antibody can be obtained according to the fluorescence intensity.

[0060] The detection card of the present application utilizes fluorescent microspheres for labeling to improve detection sensitivity and reduce nonspecific binding, and has a simple operation process, short detection time, and low detection cost.

[0061] Based on the above-mentioned multi-test card for detecting diabetes typing, the present application also shows a method for preparing a multi-test card for detecting diabetes typing, comprising the following steps:

[0062] Step S10, preparing a sample pad 2, a binding pad 3, a reaction membrane 4 and an absorption pad 9, and setting a first detection line 5, a second detection line 6, a third detection line 7 and a quality control line 8 parallel to each other on the reaction membrane 4;

[0063] Step S20, the reaction membrane 4 is arranged on the bottom plate 1, one end of the conjugation pad 3 is overlapped on one end of the reaction membrane 4 close to the detection line, one end of the absorption pad 9 is overlapped on the other end of the reaction membrane 4 close to the quality control line, and one end of the sample pad 2 is overlapped on the other end of the conjugation pad 2 to form a test strip;

[0064] Use the test strips to assemble and get the test card.

[0065] Wherein, the sample pad 2 is prepared by the following steps:

[0066] The glass cellulose membrane is soaked in a surfactant buffer and dried at a temperature of 18 to 26° C. and a relative humidity of ≤30% to prepare a sample pad.

[0067] For example, the glass fiber membrane was pretreated by soaking it in 0.2 M boric acid-borax buffer containing BSA and Tween-20 with a pH value of 8.0±0.05, and then dried overnight at a temperature of (18-26)°C and a relative humidity of ≤30% for (16-24) hours to obtain a sample pad 2.

[0068] The bonding pad 3 is prepared by the following steps:

[0069] Glutamate decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen respectively labeled with fluorescent microspheres are mixed to obtain labeled antigens; the labeled antigens are uniformly sprayed on the pretreated glass cellulose membrane using a quantitative film sprayer, and after drying, a conjugate pad 3 is obtained.

[0070] For example, the prepared fluorescent microsphere-labeled glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen were fully mixed, and then evenly sprayed on the pretreated glass cellulose membrane at 4 μL / cm using a quantitative film sprayer, and placed in an environment with a temperature of (37±2)°C and a humidity of ≤30% to dry overnight (16-24) hours to obtain a conjugate pad 3.

[0071] The reaction film 4 is prepared by the following steps:

[0072] Using coating solution, the goat anti-mouse IgG monoclonal antibody and glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen are diluted to preset concentrations to obtain antibody dilution solution, glutamic acid decarboxylase antigen dilution solution, insulin antigen dilution solution and pancreatic islet cell autoantigen dilution solution;

[0073] The antibody diluent, glutamic acid decarboxylase antigen diluent, insulin antigen diluent and islet cell autoantigen diluent are uniformly sprayed on the nitrocellulose membrane using a quantitative film sprayer to form a quality control line, a first detection line, a second detection line and a third detection line parallel to each other, and a reaction membrane 4 is obtained after drying.

[0074] The coating solution is a PBS buffer containing sucrose, the concentration of sucrose is 0.01 M, the concentration of PBS buffer is 0.01 M, and the pH value is 7.4.

[0075] For example, sheep anti-mouse IgG monoclonal antibody and glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen were diluted to a concentration of 1 mg / ml using coating solution, the distance between C line and T line was (5±0.5) mm, and 1.0 μL / cm was evenly sprayed on the nitrocellulose membrane using a quantitative film sprayer, and then placed in an electric heated air drying oven at a temperature of (37±2)°C and a humidity of ≤30% to dry for (16-24) h to obtain a reaction membrane 4.

[0076] The sample pad 2, the conjugate pad 3, the reaction membrane 4 and the absorption pad 9 are assembled as follows:

[0077] The test strips are assembled under the condition of humidity less than 35% and temperature between 20 and 30° C. The sample pad 2, the binding pad 3, the reaction membrane 4 and the absorption pad 9 are sequentially connected in the direction of the adhesive surface of the bottom plate 1 and the adjacent parts are partially overlapped.

[0078] When the reaction membrane 4 is adhered to the bottom plate 1, the first detection line 5 is located close to the binding pad, followed by the first detection line 5, the second detection line 6, the third detection line 7 and the quality control line 8. The quality control line 8 is located close to the absorption pad 9. After assembly, it is cut into test strips with a width of (3.85±0.05) mm.

[0079] It should be noted that the test strip is correctly installed on the bottom plate 1, the absorbent pad 9 should be installed at the terminal of the bottom plate, placed on the shell pressing device and pressed firmly to obtain the test strip for use.

[0080] When the test strip is placed in the receiving cavity 11 of the card housing 10, the sample pad 2 is exposed through the sample addition hole 13, and the reaction membrane 4 is exposed through the observation window 12, and the test card is assembled.

[0081] The preparation method of the multi-test card for detecting diabetes typing of the present application has a simple preparation process and can be mass-produced.

[0082] The present application also provides a multiplex test kit for detecting diabetes typing, the kit comprising the multiplex test card for detecting diabetes typing as described above, a diluent and a chip;

[0083] The diluent is phosphate buffer; the chip contains standard curve information corresponding to the test glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen.

[0084] The diluent is used to dilute the serum sample to be tested, and the chip stores the reagent standard curve information.

[0085] In this embodiment, the process of entering the standard curve information into the chip is as follows:

[0086] Take the test cards and diluents that have passed the intermediate product test, GAD antibody, IAA antibody, and ICA antibody calibrators. Each calibrator has at least 5 concentrations, and each concentration is tested at least 3 times. Calculate the mean of the T / C values ​​obtained from the test.

[0087] The prepared concentration and the corresponding T / C mean are used as linear data (i.e., standard curve information), and the data are substituted into the dedicated software to burn the chip and affix the chip label.

[0088] The detection principle of the kit of this application is as follows:

[0089] During the test, the sample is mixed with the diluent and dripped into the sample addition hole 13 of the test card. Chromatography is performed under the capillary effect. The GAD antibody, IAA antibody, and ICA antibody in the sample are combined with the glutamic acid decarboxylase antigen labeled with fluorescent microspheres, the insulin antigen labeled with fluorescent microspheres, and the pancreatic islet cell autoantigen labeled with fluorescent microspheres, diffuse to the reaction membrane 4 in the test area, and are captured by the GAD antigen, IAA antigen, and ICA antigen coated on the first test line 5, the second test line 6, and the third test line 7 to form an "antigen-antibody-fluorescent antigen" complex. The concentration of the GAD antibody, IAA antibody, and ICA antibody in the sample is proportional to the fluorescence intensity of the complex. According to the set standard curve, the immunofluorescence analyzer converts the fluorescence signal value into the concentration of the GAD antibody, IAA antibody, and ICA antibody in the sample.

[0090] The preparation method of the test kit of the present application is simple, can realize batch production, is conducive to large-scale promotion and application, and has broad market prospects.

[0091] Based on the above-mentioned multiple test kit for detecting diabetes typing, the present application provides a method for determining the multiple test kit for detecting diabetes typing, comprising the following steps:

[0092] Add the collected sample into the diluent and mix evenly to obtain a mixed sample;

[0093] Add the mixed sample to the test card, let it stand for a preset time, and then insert the test card into the immunofluorescence analyzer to obtain the test results;

[0094] The test results are calculated according to the standard curve information in the chip to obtain the contents of glutamic acid decarboxylase antibodies, insulin antibodies and islet cell autoantibodies in the sample.

[0095] Among them, the sample is a serum sample to be tested.

[0096] When the above kit is used to detect the content of glutamic acid decarboxylase antibodies, insulin antibodies and pancreatic islet cell autoantibodies in human serum samples, the reaction parameters shown in Table 1 are followed. Specifically, the serum sample to be tested is added to a phosphate buffer solution for mixing to obtain a mixed sample, and the mixed sample is added to the sample pad 2 of the test strip through the sample addition hole 13. After 10-15 minutes, the test result is displayed through the observation window 12. Then, after the test card is inserted into the matching immunofluorescence analyzer, the immunofluorescence analyzer converts the fluorescence signal value into the concentration of glutamic acid decarboxylase antibodies, insulin antibodies and pancreatic islet cell autoantibodies in the serum sample according to the set standard curve.

[0097] Table 1 Reaction parameters

[0098] Sample Type Sample size Sample volume Reaction time Reaction temperature serum 100μL 100μL 10-15min 18~30℃

[0099] The following is a more specific description of the content of the present application in conjunction with specific embodiments, and further elaboration of the present application, but these embodiments are by no means limiting the present application.

[0100] Example 1

[0101] This embodiment is a multiple-test kit for detecting diabetes typing. The components, packaging and quantity (25 servings / box) of the kit are shown in Table 2.

[0102] Table 2 Composition, packaging and quantity of the kit

[0103]

[0104]

[0105] Example 2

[0106] In this example, the performance indicators of the kit of Example 1 were measured.

[0107] The performance index requirements of the kit of this application are as follows:

[0108] Detection limit: should not be higher than 1.0IU / mL.

[0109] Accuracy: The ratio of the mean value of the measured value to the theoretical value of the GAD-Ab, IAA, and ICA reference products should be between 0.85 and 1.15, and the relative deviation should be within ±15%.

[0110] Intra-assay precision: The intra-batch coefficient of variation (CV) should be ≤15%.

[0111] Reference range: GAD-Ab≤7.18IU / mL, IAA≤12.53IU / mL, ICA≤19.17IU / mL.

[0112] The performance index measurement data are as follows:

[0113] 1. Detection limit test

[0114] The minimum detection limit test results (IU / mL) are shown in Table 3.

[0115] Table 3

[0116]

[0117]

[0118] 2. Accuracy test

[0119] The accuracy test results are shown in Table 4.

[0120] Table 4

[0121]

[0122]

[0123] It can be seen from the data in the above table that the relative deviation of the test kit is within ±10%, indicating that the accuracy of the test kit of this application meets the requirements.

[0124] 3. Precision test

[0125] In this example, the internal precision of the kit was analyzed, and the results are shown in Table 5.

[0126] Table 5

[0127]

[0128] It can be seen from the data in the above table that the intra-batch coefficient of variation (CV) is ≤15%, indicating that the kit of the present application has high precision and good repeatability.

[0129] In summary, the test kit of the present application can obtain the accuracy and stability of the results of the current mature and stable ELISA test kit method, and has higher sensitivity and shorter detection time than the ELISA test kit method, simplifies the operating steps of the detection of the markers of diabetes typing, glutamic acid decarboxylase antibody (GAD-Ab), insulin autoantibodies (IAA), and islet cell antibodies (ICA), and saves detection time. The test kit only needs to mix the sample with the diluent, add the mixed solution to the test card and read the data with a fluorescent instrument, without various supporting reagents or expensive instruments. Therefore, the test kit has the characteristics of fast, sensitive, easy to operate, low cost, and wide application prospects.

[0130] Obviously, the embodiments described above are only some embodiments of the present application, rather than all embodiments. The preferred embodiments of the present application are given in the accompanying drawings, but they do not limit the patent scope of the present application. The present application can be implemented in many different forms. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive. Although the present application is described in detail with reference to the aforementioned embodiments, for those skilled in the art, it is still possible to modify the technical solutions recorded in the aforementioned specific implementation methods, or to perform equivalent replacement of some of the technical features therein. Any equivalent structure made using the contents of the specification and drawings of this application, directly or indirectly used in other related technical fields, is similarly within the scope of patent protection of this application.

Claims

1. A multi-test card for detecting diabetes typing, characterized in that: The test card comprises a test strip, and the test strip comprises a sample pad, a conjugate pad, a reaction membrane, an absorption pad and a bottom plate; The bottom plate is a long strip structure, the reaction membrane is arranged on the surface of the bottom plate, one end of the binding pad is overlapped on one end of the reaction membrane, one end of the absorption pad is overlapped on the other end of the reaction membrane, one end of the sample pad is overlapped on the other end of the binding pad, and the sample pad and the absorption pad are respectively arranged at two ends of the bottom plate; a first detection line, a second detection line, a third detection line and a quality control line are arranged on the reaction membrane in parallel with each other; Among them, the binding pad is coated with glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen respectively labeled with fluorescent microspheres; the first detection line is coated with glutamic acid decarboxylase antigen; the second detection line is coated with insulin antigen; the third detection line is coated with pancreatic islet cell autoantigen; the quality control line is coated with sheep anti-mouse IgG monoclonal antibody.

2. The multi-test card for detecting diabetes typing according to claim 1, characterized in that: The sample pad is made of a glass cellulose membrane soaked in a surfactant buffer.

3. The multi-test card for detecting diabetes typing according to claim 2, characterized in that: The surfactant buffer is selected from a boric acid-borax buffer containing bovine serum albumin and Tween 20.

4. The multi-test card for detecting diabetes typing according to claim 1, characterized in that: The binding pad is made of glass cellulose membrane; the reaction membrane is made of nitrocellulose membrane; and the absorption pad is made of H-1 absorbent paper.

5. The multiple-test card for detecting diabetes typing according to any one of claims 1 to 4, characterized in that: The detection card further comprises a card shell, which comprises a receiving cavity, a sample adding hole and an observation window; the sample adding hole and the observation window are respectively connected with the receiving cavity; The test strip is placed in the receiving cavity, the sample adding hole corresponds to the sample pad area, and the observation window corresponds to the reaction membrane area.

6. A method for preparing a multiplex test card for detecting diabetes typing, characterized in that: The following steps are involved: A sample pad, a conjugation pad, a reaction membrane and an absorption pad are prepared, wherein a first detection line, a second detection line, a third detection line and a quality control line are arranged on the reaction membrane in parallel, wherein the conjugation pad is coated with glutamic acid decarboxylase antigen, insulin antigen and islet cell autoantigen respectively labeled with fluorescent microspheres, the first detection line is coated with glutamic acid decarboxylase antigen, the second detection line is coated with insulin antigen, the third detection line is coated with islet cell autoantigen, and the quality control line is coated with goat anti-mouse IgG monoclonal antibody; The reaction membrane is arranged on the bottom plate, one end of the conjugate pad is overlapped on one end of the reaction membrane close to the detection line, one end of the absorption pad is overlapped on the other end of the reaction membrane close to the quality control line, and one end of the sample pad is overlapped on the other end of the conjugate pad to form a test strip; Use the test strips to assemble and get the test card.

7. The method for preparing a multiple-test card for detecting diabetes typing according to claim 6, characterized in that: The sample pad is prepared by the following steps: The glass cellulose membrane is soaked in a surfactant buffer and dried at a temperature of 18 to 26° C. and a relative humidity of ≤30% to prepare a sample pad; The conjugate pad is prepared by the following steps: Mixing glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen respectively labeled with fluorescent microspheres to obtain labeled antigens; Using a quantitative film sprayer, spraying the labeled antigen onto the pretreated glass cellulose membrane at a uniform speed, and preparing a conjugate pad after drying; The reaction film is prepared by the following steps: Using coating solution, the goat anti-mouse IgG monoclonal antibody and glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen are diluted to preset concentrations to obtain antibody dilution solution, glutamic acid decarboxylase antigen dilution solution, insulin antigen dilution solution and pancreatic islet cell autoantigen dilution solution; The antibody dilution, the glutamic acid decarboxylase antigen dilution, the insulin antigen dilution and the pancreatic islet cell autoantigen dilution are uniformly sprayed on the nitrocellulose membrane using a quantitative film sprayer to form a quality control line, a first detection line, a second detection line and a third detection line which are parallel to each other, and a reaction membrane is obtained after drying.

8. The method for preparing a multiplex test card for detecting diabetes typing according to claim 6, characterized in that: The coating solution is PBS buffer containing sucrose.

9. A multiplex test kit for detecting diabetes typing, characterized in that: It comprises the multiple-test card for detecting diabetes typing, a diluent and a chip as claimed in any one of claims 1 to 5; The diluent is a phosphate buffer; the chip contains standard curve information corresponding to the test glutamic acid decarboxylase antigen, insulin antigen and pancreatic islet cell autoantigen.

10. A method for detecting diabetes typing using a multiplex test kit, characterized in that: The following steps are involved: Add the collected sample into the diluent and mix evenly to obtain a mixed sample; Add the mixed sample to the test card, let it stand for a preset time, and then insert the test card into an immunofluorescence analyzer to obtain the test result; The test results are calculated according to the standard curve information in the chip to obtain the contents of glutamic acid decarboxylase antibodies, insulin antibodies and islet cell autoantibodies in the sample respectively.

Citation Information

Patent Citations

  • Kit for combined detection of 6 diabetic antibodies

    CN102967704A

  • Fluorescent immunochromatographic detection card and kit for early-stage breast cancer multi-detection

    CN109270269A

  • Kit for quantitatively detecting cTnT / NT-proBNP / D-dimer and application thereof

    CN114034854A

  • Insulin fluorescence immunochromatography assay kit and preparation method thereof

    CN115389761A

  • 1-type diabetes auto-antibody spectrum detection test paper

    CN202631539U

Cited By

  • Preparation method and application of dry chemical reagent for measuring urea stored at normal temperature

    CN119310073A